SLXN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
SLXN is not a good buy right now for an impatient investor. The tape is bearish (downtrend across moving averages, weakening MACD) and the stock is trading below a key support area (~1.90), with no near-term news catalysts and no proprietary Intellectia buy signals today. Despite one bullish analyst initiation with a $6 target, the current setup favors avoiding/stepping aside rather than buying immediately.
Trend/structure: Bearish. Moving averages are stacked bearishly (SMA_200 > SMA_20 > SMA_5), indicating sustained downside momentum. Momentum: MACD histogram is negative (-0.00361) and expanding lower, confirming accelerating bearish momentum. RSI: RSI_6 at ~27.94 is near oversold territory (can enable bounces), but oversold alone is not a buy trigger in a strong downtrend. Key levels: Current price 1.84 is below S1 (1.899) and below the pivot (2.143). Next downside support is S2 (1.748). Overhead resistance sits at ~2.14 (pivot) then ~2.39 (R1). Pattern/short-term probability: Similar-pattern projection suggests a slightly negative next day (-0.49%) but positive skew over 1 week (+11.37%) and 1 month (+18.32%). However, with price under broken support and bearish MAs, the higher-timeframe rebound case lacks confirmation.
Intellectia Proprietary Trading Signals Intellectia Proprietary Trading Signals
Analyst initiation: Litchfield Hills initiated Buy with a $6 price target (2025-12-15), citing an siRNA platform targeting KRAS-driven cancers and a path toward late-stage clinical development with planned regulatory submissions (Israel MoH in Q4; Germany/EU in Q1).
Potential technical bounce factor: RSI near oversold levels can spark short-lived rebounds if buyers reclaim ~1.90 and then the ~2.14 pivot.
with bearish MA alignment and weakening MACD, increasing risk of continuation toward S2 (~1.75).
Latest quarter: 2025/Q3. Revenue: 0 (no growth base). Profitability: Net income -$3.262M (down 72.5% YoY, i.e., larger loss). EPS: -2.88 (down 97.99% YoY), indicating sharply worsening per-share losses. Overall: Pre-revenue profile with deteriorating losses in the latest quarter, which weakens the fundamental near-term support for buying on weakness.
Recent trend: A single notable update—on 2025-12-15 Litchfield Hills initiated coverage with a Buy rating and a $6 price target. Wall Street-style pro view: Large upside potential if the KRAS siRNA approach validates clinically and regulatory filings progress as outlined. Wall Street-style con view: Execution and clinical/regulatory risk typical of early-stage therapeutics; lack of revenue and worsening losses (2025/Q3) make the stock highly dependent on future milestones rather than current financial strength.
